p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells
Authors
Keywords
-
Journal
JOURNAL OF EXPERIMENTAL MEDICINE
Volume 210, Issue 10, Pages 2057-2069
Publisher
Rockefeller University Press
Online
2013-09-17
DOI
10.1084/jem.20130783
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Regulation of Ligands for the NKG2D Activating Receptor
- (2013) David H. Raulet et al. Annual Review of Immunology
- Non-Cell-Autonomous Tumor Suppression by p53
- (2013) Amaia Lujambio et al. CELL
- p53 is an Important Regulator of CCL2 Gene Expression
- (2012) X. Tang et al. CURRENT MOLECULAR MEDICINE
- RAE-1 ligands for the NKG2D receptor are regulated by E2F transcription factors, which control cell cycle entry
- (2012) Heiyoun Jung et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Comprehensive Analysis of NKG2D Ligand Expression and Release in Leukemia: Implications for NKG2D-Mediated NK Cell Responses
- (2012) J. Hilpert et al. JOURNAL OF IMMUNOLOGY
- Granule exocytosis mediates immune surveillance of senescent cells
- (2012) A Sagiv et al. ONCOGENE
- Regulatory T Cells Increase the Avidity of Primary CD8+ T Cell Responses and Promote Memory
- (2012) L. Pace et al. SCIENCE
- Human NK Cells Are Alerted to Induction of p53 in Cancer Cells by Upregulation of the NKG2D Ligands ULBP1 and ULBP2
- (2011) S. Textor et al. CANCER RESEARCH
- Distinct p53 Transcriptional Programs Dictate Acute DNA-Damage Responses and Tumor Suppression
- (2011) Colleen A. Brady et al. CELL
- Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2
- (2011) Hai Li et al. CELL CYCLE
- Four faces of cellular senescence
- (2011) Francis Rodier et al. JOURNAL OF CELL BIOLOGY
- Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
- (2011) Tae-Won Kang et al. NATURE
- Innate or Adaptive Immunity? The Example of Natural Killer Cells
- (2011) E. Vivier et al. SCIENCE
- G-protein-coupled receptors in control of natural killer cell migration
- (2011) Thierry Walzer et al. TRENDS IN IMMUNOLOGY
- Expression of the RAE-1 Family of Stimulatory NK-Cell Ligands Requires Activation of the PI3K Pathway during Viral Infection and Transformation
- (2011) Maria Tokuyama et al. PLoS Pathogens
- DNA-SCARS: distinct nuclear structures that sustain damage-induced senescence growth arrest and inflammatory cytokine secretion
- (2010) F. Rodier et al. JOURNAL OF CELL SCIENCE
- Regulation of MCP-1 chemokine transcription by p53
- (2010) Katrin Hacke et al. Molecular Cancer
- NKG2D Ligand Expression in Human Colorectal Cancer Reveals Associations with Prognosis and Evidence for Immunoediting
- (2009) R. W. McGilvray et al. CLINICAL CANCER RESEARCH
- Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion
- (2009) Francis Rodier et al. NATURE CELL BIOLOGY
- Oncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory Network
- (2008) Thomas Kuilman et al. CELL
- Oncogenic BRAF Induces Senescence and Apoptosis through Pathways Mediated by the Secreted Protein IGFBP7
- (2008) Narendra Wajapeyee et al. CELL
- Chemokine Signaling via the CXCR2 Receptor Reinforces Senescence
- (2008) Juan C. Acosta et al. CELL
- Senescence of Activated Stellate Cells Limits Liver Fibrosis
- (2008) Valery Krizhanovsky et al. CELL
- NKG2D-Deficient Mice Are Defective in Tumor Surveillance in Models of Spontaneous Malignancy
- (2008) Nadia Guerra et al. IMMUNITY
- Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
- (2008) Jean-Philippe Coppé et al. PLOS BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started